We are live on ! Find out more
NVRO

NEVRO CORP.
NVRO

Delisted

NVRO was delisted on the 2nd of April, 2025.

Back to rankings

207 hedge funds and large institutions have $6.36B invested in NEVRO CORP. in 2021 Q2 according to their latest regulatory filings, with 38 funds opening new positions, 75 increasing their positions, 64 reducing their positions, and 35 closing their positions.

New
Increased
Maintained
Reduced
Closed

21% more capital invested

Capital invested by funds: $5.24B → $6.36B (+$1.12B)

17% more repeat investments, than reductions

Existing positions increased: 75 | Existing positions reduced: 64

14% more call options, than puts

Call options by funds: $34.8M | Put options by funds: $30.5M

1% more funds holding

Funds holding: 204 → 207 (+3)

9% more first-time investments, than exits

New positions opened: 38 | Existing positions closed: 35

Holders
207
Holders Change
+3
Holders Change %
+1.47%
% of All Funds
3.59%
Holding in Top 10
1
Holding in Top 10 Change
+1
Holding in Top 10 Change %
% of All Funds
0.02%
New
38
Increased
75
Reduced
64
Closed
35
Calls
$34.8M
Puts
$30.5M
Net Calls
+$4.31M
Net Calls Change
-$5.25M

Top Buyers

Rank Fund Capital Flow
1
HM
HealthCor Management
New York
+$58.7M
2
JSP
Jackson Square Partners
California
+$45.8M
3
FAM
Fred Alger Management
New York
+$44.9M
4
Fidelity Investments
Fidelity Investments
Massachusetts
+$43.9M
5
Wellington Management Group
Wellington Management Group
Massachusetts
+$38.4M

Top Sellers

Rank Fund Capital Flow
1
Citadel Advisors
Citadel Advisors
Florida
-$43.3M
2
Morgan Stanley
Morgan Stanley
New York
-$37.2M
3
Goldman Sachs
Goldman Sachs
New York
-$36.5M
4
Norges Bank
Norges Bank
Norway
-$28.5M
5
Bank of America
Bank of America
North Carolina
-$26M

NVRO Hedge Fund Activity: Q2 2021 in Review

207 of the 5,767 institutional investors tracked by Wall St. Rank reported a position in NEVRO CORP. (NVRO) for Q2 2021, worth a combined $6.36B — up 21% from $5.24B a quarter earlier.

Buyers outnumbered sellers: 38 funds opened new NVRO positions and 35 closed out — a net gain of 3 holders — while 75 added to existing stakes and 64 trimmed.

The largest buyer was HealthCor Management, opening a new position worth an estimated $58.7M. The largest seller was Citadel Advisors, exiting entirely with an estimated $43.3M sold.

  • 207 institutional investors held NEVRO CORP. (NVRO) as of Q2 2021, up from 204 in Q1 2021.
  • Funds reported $6.36B of NEVRO CORP. stock for Q2 2021, up 21% quarter-over-quarter.
  • 38 funds opened new NEVRO CORP. positions in Q2 2021 and 35 closed out, a net change of +3 holders.
  • The largest NEVRO CORP. buyer in Q2 2021 was HealthCor Management, an estimated $58.7M added.
  • The largest NEVRO CORP. seller in Q2 2021 was Citadel Advisors, an estimated $43.3M sold.

Based on aggregated 13F filings for Q2 2021.